Acetylcholine-binding protein (AChBP) from the mollusc Lymnaea stagnalis is at present the only high-resolution model for the ligand-binding domains of the ligand-gated ion channel family, which includes nicotinic acetylcholine, 5HT3, GABAA, GABAC and glycine receptors.
Structure-based drug design is usually described as an iterative process in which knowledge of the three-dimensional structure of a receptor-ligand complex reveals details of the binding interface that can be improved by chemical modification of the ligand. These structure-based changes as evaluated by in vitro or in vivo assay, and improved ligands are subjected to additional cycles of structure determination, improvement and evaluation. Our studies on caspase-3, PTP-1B and other targets provide examples of such classical structure-based drug design. On occasion, however, structural studies lead to surprising results that produce unexpected effects on the inhibitor-development process. In both the caspase and PTP projects, early structures revealed that the apparent improvement in binding potency was inconsistent with program goals and this knowledge led to termination of the compound classes involved. In work on both nuclear receptors and kinases, knowledge of structure-based selectivity led to the design of novel assays that have effectively discriminated compounds on their biological properties. These studies demonstrate that structure-based drug design studies can not only lead to ligand optimization but to prioritization of compound classes and to the design of novel methods of discriminating among compounds based on their biological properties. as an important therapeutic target. It is composed of the conserved Cterminal, zinc containing, catalytic domain, which catalyses the cleavage of cGMP, and an N-terminal regulatory portion, which contains two GAF domain repeats [1] . Each GAF domain contains a cGMP-binding site, one of high affinity and the other of lower affinity [2] . PDE5 activity is regulated through binding of cGMP to the high and low affinity cGMP binding sites followed by phosphorylation, which occurs only when both sites are occupied [3] . PDE5 is found in varying concentrations in a number of tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle. The protein is a key regulator of cGMP levels in the smooth muscle of the erectile corpus cavernosal tissue. Inhibition of PDE5 inhibits the breakdown of cGMP allowing the levels of cGMP, and hence smooth muscle relaxation, to be maintained [2] . Sildenafil, the active ingredient of Viagra and a potent inhibitor of PDE5, has attracted widespread attention for the effective treatment of male erectile dysfunction.
We present here the application of the structures of PDE5 [4-9] to design novel inhibitors. The use of the complexes provides additional important structural information on the binding modes of multiple series of inhibitors. The structures also highlight the diverse chemical nature of inhibitors within this gene target and wider gene family, and the subtle structure activity relationships which assist the design of more potent and specific inhibitors to treat the many diseases where PDE's play a role. Structural GenomiX, Inc. (SGX) has developed an integrated target-to-lead platform that combines high-throughput X-ray crystallography with a fragment-based approach to lead identification/optimization. The proprietary FAST™ (Fragments of Active Structures) process exploits crystallographic screening to detect, visualize, and identify small ligands (MW 150-200) that are bound to the target protein. Each member of the FAST™ fragment/scaffold library was designed to be amenable to rapid chemical elaboration at two or three points of chemical diversity using high-throughput organic synthesis. Initial lead optimization involves using our knowledge of the co-crystal structure of the target-fragment complex and advanced computational chemistry tools to guide synthesis of small focused linear (one-dimensional) libraries. These linearly elaborated fragments/scaffolds are then evaluated with in vitro biochemical and cellular assays and co-crystallography. Thereafter, optimal variations at each point of chemical diversity are combined to synthesize focused combinatorial (two-or three-dimensional) libraries that are again examined with assays and co-crystallography. (The potential chemical diversity of the fully elaborated FAST™ fragment/scaffold library far exceeds 160 million compounds.) These focused combinatorial libraries typically contain multiple novel compounds of low molecular weight (<350) that bind the target protein at low nM IC 50 and already display considerable selectivity. Thereafter, compound series are prioritized for further medicinal chemistry and compound development efforts using the results of in vitro and in vivo ADME and in vitro toxicology studies in concert with structural information. Successful applications of the FAST™ fragment-based lead discovery/optimization process will be presented
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